Table 1.
Major characteristics of PLCO and the two chemoprevention trials.
| PLCO | PCPT | REDUCE | |
|---|---|---|---|
| Number randomized | 38,350 1 | 18,882 | 8,231 |
| Years enrolled | 1993-2001 | 1994-1997 | Not reported |
| Mean age (SD) | 62 (5) | 63 (6) | 63 (6) |
| Baseline eligibility criteria 2 | Less than 2 prior PSA tests 3 | PSA < 3 ng/ml | Single Negative Biopsy; PSA 2.5 to 10 ng/ml 4 |
| PSA Testing Schedule | Annual (for 6 years) | Annual (for 7 years) | Every 6 months (for 4 yrs) |
| Biopsy | For cause | For cause and end-of-study | For cause, year 2 and year 4 |
1
Intervention (screening) arm only
2
All trials excluded men with prior prostate cancer diagnosis
3
About 10% of men were randomized before the time (April, 1995) that this criterion went into effect
4
PSA 3.0-10.0 ng/ml for men over age 60